EC-D (epirubicin/cyclophosphamide followed by docetaxel)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for EC-D (epirubicin/cyclophosphamide followed by docetaxel), covering 2022-09-01 to 2022-09-01. Get the full timeline:
Most recent: Clinical Trial Update: DCb (Docetaxel/Carboplatin) Versus EC-D (Epirubicin/Cyclophosphamide Followed by Docetaxe) as Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer [Phase 2]